MedPath

To study the oxidant-antioxidant status in vitiligo patients

Not Applicable
Completed
Conditions
Health Condition 1: null- Vitiligo
Registration Number
CTRI/2013/01/003312
Lead Sponsor
Employees State Insurance Corporation Post Graduate Institute of Medical Sciences Research
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
150
Inclusion Criteria

1. Patients with vitiligo attending dermatology outpatient clinic

2. Age group 18-45 years (at the time of entry into study)

3. Constant dietary habits for the past 1 year

Exclusion Criteria

1. Cigarette smoking

2. Alcohol intake during past 3 months

3. Intake of folic acid, vitamin B6 and B12 during past 2 months

4. Intake of antioxidant supplements during past 3 months

5. Any systemic disease associated with altered serum Hcy levels. This will include known cases of cardiovascular disease, renal failure, diabetes mellitus, hypertension, hypothyroidism, hyperthyroidism & chronic liver disease and patients with any relevant findings on general and systemic examination.

6. Dermatological diseases known to affect serum Hcy levels, including psoriasis, Behcetâ??s disease, SLE.

7. Intake of any drugs known to affect Hcy levels, including methotrexate, INH, isotretinoin, cyclosporine, penicillamine, phenytoin, carbamazepine, OCPs, hydralazine, L-dopa, procarbazine, acetylcysteine, cholestyramine and cycloserine.

8. Pregnant females and females in 1-week postpartum period

9. Patients with any haematological or biochemical abnormality observed during routine laboratory investigations

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare levels of serum homocysteine and total antioxidant status of cases to those of controlsTimepoint: 10 months
Secondary Outcome Measures
NameTimeMethod
To correlate levels of serum homocysteine and serum antioxidant status in vitiligo patients with the activity of the diseaseTimepoint: 10 months
© Copyright 2025. All Rights Reserved by MedPath